NJ-DAIICHI-SANKYO-CO
22.7.2020 08:02:15 CEST | Business Wire | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs), in lung and breast cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200721005963/en/
The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic breast cancer.
“We look forward to engaging and collaborating with the deep expertise and cutting-edge oncology research capabilities of Gustave Roussy, the premier European Cancer Center, to further advance clinical development of DS-1062 and patritumab deruxtecan,” said Antoine Yver, MD, MSc, AIHP, ACCA Paris, Global Head, Oncology R&D, Daiichi Sankyo. “This innovative research program includes two precision-medicine rich phase 2 trials designed with an adaptive approach to help determine which patients are most likely to benefit from our ADCs with optimal speed and efficiency. Combination therapy strategies will also be explored in other studies.”
“This partnership is strategic for Gustave Roussy and it brings together all the skills which are essential for top quality research in oncology. Launching clinical trials to test two promising molecules in advanced non-small cell lung cancer and metastatic breast cancer is essential for diseases which unfortunately have an increasing incidence and for which there is an urgent need to make progress,” said Prof. Jean-Charles Soria, General Director of Gustave Roussy. "It is by pushing the boundaries of innovation that we will further improve the quality of care for our patients."
About the Collaboration
Under the agreement, Daiichi Sankyo, Inc. will provide funding and support to Gustave Roussy for a comprehensive, integrative research program including clinical, translational and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer, respectively.
Two adaptive phase 2 trials will be conducted, including a multicenter, open-label study to evaluate efficacy, safety and markers of response and resistance to DS-1062 in patients with advanced NSCLC who have progressed on anti-PD-1/PD-L1 therapy and platinum-doublet chemotherapy.
The second multicenter, open-label phase 2 study will evaluate the efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan in patients with HER3 expressing metastatic breast cancer.
Each study will enroll up to 100 patients and will be conducted in several sites in France.
The primary endpoint for both studies is objective response rate as assessed by independent central review. Secondary endpoints include clinical benefit rate, progression-free survival, duration of response, overall survival and safety measures. The studies also will primarily be conducted to analyze biomarker expression and tumor sensitivity; the role of receptor biology in the pharmacological activity of the Daiichi Sankyo DXd ADC platform, as well as factors contributing to treatment resistance; immunogenicity and mechanism of action.
The adaptive trial design includes ongoing clinical and biomarker assessments to identify factors associated with individual patient response and the ability to fine-tune development accordingly.
Additional research to be conducted under the collaboration includes several studies exploring multiple therapeutic combinations for each ADC.
About Gustave Roussy
Gustave Roussy, Europe's leading cancer center, is a global cancer center of expertise entirely dedicated to patients. It brings together 3,100 professionals whose missions are care, research and teaching. The Institute has expertise in the management of rare cancers and complex tumors. It treats all cancers at every stage of life and offers its patients individualized care combining innovation and a humane approach. Twenty-six percent of its new patients are included in clinical trials. For more information, please visit: www.gustaveroussy.fr/en .
About DS-1062 and Patritumab Deruxtecan (U3-1402)
DS-1062 and patritumab deruxtecan (U3-1402) are two of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
Designed with Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is comprised of a humanized anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker. Patritumab deruxtecan is comprised of a human anti-HER3 antibody and the same payload and linker as DS-1062.
DS-1062 is currently being evaluated in a phase 1 trial in patients with advanced solid tumors that are refractory to or relapsed from standard treatment or for whom no standard treatment is available. The study is currently enrolling patients with unresectable advanced NSCLC and unresectable/advanced or metastatic triple negative breast cancer.
Patritumab deruxtecan is currently being evaluated in a phase 1 study in previously treated patients with metastatic or unresectable NSCLC. Patritumab deruxtecan is also being evaluated in a phase 1/2 study in patients with HER3 expressing metastatic breast cancer.
DS-1062 and patritumab deruxtecan are investigational agents that have not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com .
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005963/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ruler of Ras Al Khaimah Inaugurates the First Ras Al Khaimah’s Business Consultancy in China, Strengthening Ties With Guangdong21.10.2026 23:46:00 CEST | Press release
HH Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, marking a new chapter of cooperation and partnership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021542126/en/ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, located in Guangzhou, Guangdong Province, stating that the launch reflects a long-term commitment to strengthening ties with partners in China and to creating new avenues for investment, trade and collaboration. (Photo: AETOSWire) Located in the industrial hub of Guangzhou, the consultancy will serve as a leading platform dedicated to strengthening Ras Al Khaimah’s engagement with Chinese businesses, facilitating expanding cooperation across key sectors. The inauguration builds on a relationship t
Octane AI Launches Phoenix, an AI Quiz Builder That Builds, Checks and Improves Quizzes for Shopify Brands21.10.2026 19:15:00 CEST | Press release
Phoenix builds a full quiz from a prompt or a document, catches broken logic before shoppers do and shows what every answer earns in Shopify revenue. Octane AI, the quiz and zero-party data platform for Shopify brands, launched Phoenix in October, its biggest release to date. Merchants describe the quiz they want or upload what they already have, and Phoenix builds it, checks it, personalizes the results and keeps improving it with experiments. One beta customer turned a single document into a complete product-launch quiz: “I attached it to Phoenix, and it built the whole thing, all the pages. It understood everything, not just the text but the logic behind it.” Across all live Octane AI quizzes, 15% of shoppers who finish a quiz place an order. Yet building one has meant hours of writing rules by hand, custom code for design and clicking through every path to find broken results. Phoenix handles those hard parts, from building a quiz to improving it after launch. “Since day one, we've
Cognite Earns Corporate Supplier of the Year Award from Marathon Petroleum Corporation21.10.2026 19:06:00 CEST | Press release
Cognite today announced it has been named Corporate Supplier of the Year winner in Marathon Petroleum Corporation’s 11th Annual Supplier Recognition Awards. The Supplier Recognition Awards is a program sponsored by Marathon Petroleum Corporation to honor suppliers that positively impacted the company’s business throughout the previous calendar year. “There’s a reason ‘Impact’ is one of Cognite’s most important core values,” said Girish Rishi, CEO of Cognite. “For us, the ultimate measure of our performance is delivering quantifiable value for our customers. From that perspective, the Corporate Supplier of the Year award from Marathon is particularly meaningful. Marathon Petroleum is an innovator, and to receive this recognition is a great honor to the Cognite community.” The Supplier of the Year Award from Marathon is the latest honor Cognite has received in 2026: In May, Cognite ranked 15th on CNBC’s Disruptor50 list, honoring venture-backed companies innovating across industries, exp
The Estée Lauder Companies Inc. to Webcast Capital Markets Experience: China Ecosystem Immersion Presentations on November 4, 202621.10.2026 18:48:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that it will webcast presentations from its Capital Markets Experience: China Ecosystem Immersion in Shanghai, China, on Wednesday, November 4, 2026. The event will feature presentations from Stéphane de La Faverie, President and Chief Executive Officer, and Akhil Shrivastava, Executive Vice President and Chief Financial Officer, as well as members of the Company’s Executive Leadership Team and local leaders. The presentations will highlight the Company’s strategy and capabilities in China, Beauty Reimagined in action, and how China serves as a blueprint for deploying the Company’s global capabilities to drive sustainable growth and stronger profitability. Due to limited capacity, in-person attendance is by invitation only. Interested parties can access the live webcast on Wednesday, November 4th, beginning at 1:00 p.m. China Standard Time (12:00 a.m. ET) at Investors – The Estée Lauder Companies Inc. A replay of the webcast wi
Future Health and Bridge for Billions to Launch Programme Strengthening Health Entrepreneurship in Emerging Markets21.10.2026 17:50:00 CEST | Press release
New programme will support locally rooted health entrepreneurs to build stronger ventures and deepen their impact in the communities they serve The programme responds to persistent gaps in capital and specialist support for promising health innovation across emerging markets First phase will target around 50 entrepreneurs leading late-incubation to early-acceleration ventures in Africa and Asia Entrepreneurs will receive tailored support, with selected groups later having the opportunity to access Abu Dhabi’s health innovations ecosystem Future Health – A Global Initiative by Abu Dhabi and Bridge for Billions will launch a new entrepreneurship programme designed to strengthen promising health ventures in emerging markets and help locally-developed solutions reach more people. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021719421/en/ The first phase of the programme will target around 50 entrepreneurs leading late-incub
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom